Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

U

Upsher-Smith Laboratories

Status and phase

Enrolling
Phase 4

Conditions

Migraine Disorders

Treatments

Drug: Placebo
Drug: Qudexy XR

Study type

Interventional

Funder types

Industry

Identifiers

NCT04748601
P255-501

Details and patient eligibility

About

A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.

Enrollment

132 estimated patients

Sex

All

Ages

6 to 11 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject is a female or male 6 to 11 years of age, inclusive, at Visit 1 (Screening)
  • Subject weighs at least 17.0 kg and less than 50.0 kg at Visit 1 (Screening) based on 95 percentile weight for the age range.11
  • Subject has at least a 6-month history of headaches consistent with a diagnosis of migraine with or without aura (International Classification of Headache Disorders, 3rd Edition [ICHD 3]).
  • Subject had ≥8 self-reported headache days in the 28 days prior to Screening.
  • Subject has a PedMIDAS score >10, indicating at least mild disruption in daily activities, and <140, indicating extreme disability that may require more comprehensive, multi component therapy.

Exclusion criteria

  • Subject has continuous migraines, defined as an unrelenting headache for a 28-day period.
  • Subject is currently receiving treatment or has used Botulinum toxin (Botox®) within 3 months prior to Visit 1 (Screening).
  • Subject is currently receiving migraine prevention medication and has initiated or changed the dose within 28 days of Screening or is unwilling to avoid making a change during the duration of the study.
  • Subject has previously failed an adequate trial of topiramate (at least 3 months duration at a clinically appropriate dose) for prophylaxis of migraine headache due to lack of efficacy or AEs.
  • Subject has previously failed an adequate trial of >3 migraine preventative medications.
  • Subject has a known history of allergic reaction to topiramate or any excipient in Qudexy XR.
  • Subject has a diagnosis or history of disease that may interfere with safety or evaluation of the study drug.
  • Subject is currently using an investigational drug or device or has used such within 30 days prior to Visit 1.

Subject has begun menses and any of the following:

  • Subject has tested positive for pregnancy; OR
  • Subject is pregnant, planning pregnancy, or lactating; OR
  • Subject is taking an oral hormonal contraceptive (either combined [estrogen and progestogen containing] or progestogen-only) and is unable or unwilling to switch to an alternative highly effective contraceptive method.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

132 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Treatment:
Drug: Placebo
Qudexy XR
Experimental group
Treatment:
Drug: Qudexy XR

Trial contacts and locations

0

Loading...

Central trial contact

PPD Laboratories

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems